EUVIMEDEUVIMED entdecken
Crossref

Exploring the Efficacy of Noncovalent SARS‐CoV‐2 Main Protease Inhibitors: A Computational Simulation Analysis Study

Fei Xiong iD, Yan-Jun Zhang, Hui-Ying Jiang, Zhong-Hua Wang

Chemistry & Biodiversity · 2024

DOI: 10.1002/cbdv.202302089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2024. Verfasst von Fei Xiong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Shanghai for Science and Technology, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Antiviral Agents, Coronavirus 3C Proteases, Molecular Docking Simulation, Molecular Dynamics Simulation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hubei Key Laboratory of Drug Synthesis and Optimization, Jing Chu University of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS‐CoV‐2 main protease, as a key target for antiviral therapeutics, is instrumental in maintaining virus stability, facilitating translation, and enabling the virus to evade innate immunity. Our research focused on designing non‐covalent inhibitors to counteract the action of this protease. Utilizing a 3D‐QSAR model and contour map, we successfully engineered eight novel non‐covalent inhibitors. Further evaluation and comparison of these novel compounds through methodologies including molecular docking, ADMET analysis, frontier molecular orbital studies, molecular dynamics simulations, and binding free energy revealed that the inhibitors N02 and N03 demonstrated superior research performance (N02 ΔG bind =−206.648 kJ/mol, N03 ΔG bind =−185.602 kJ/mol). These findings offer insightful guidance for the further refinement of molecular structures and the development of more efficacious inhibitors. Consequently, future investigations can draw upon these findings to unearth more potent inhibitors, thereby amplifying their impact in the treatment and prevention of associated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCoronavirus 3C ProteasesMolecular Docking SimulationMolecular Dynamics SimulationProtease InhibitorsQuantitative Structure-Activity RelationshipSARS-CoV-2HumansCOVID-19 Drug TreatmentMolecular StructureThermodynamics

Stichwörter der Autor:innen

ADMETDFTMD simulationsMain protease inhibitorsSARS-CoV-2

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors

Autor:innen und Institutionen

  • Department of Chemistry, University of Shanghai for Science and Technology, Shanghai, P. R. China.
  • School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, P. R. China.

ORCID-Profile: Fei Xiong

Förderung

  • National Natural Science Foundation of China
  • Hubei Key Laboratory of Drug Synthesis and Optimization, Jing Chu University of Technology

Zitieren

APA

Xiong, F., Zhang, Y. J., Jiang, H. Y., & Wang, Z. H. (2024). Exploring the Efficacy of Noncovalent SARS‐CoV‐2 Main Protease Inhibitors: A Computational Simulation Analysis Study. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202302089

Vancouver

Xiong F, Zhang YJ, Jiang HY, Wang ZH. Exploring the Efficacy of Noncovalent SARS‐CoV‐2 Main Protease Inhibitors: A Computational Simulation Analysis Study. Chemistry & Biodiversity. 2024. doi:10.1002/cbdv.202302089

BibTeX
@article{Xiong2024,
  author = {Xiong, Fei and Zhang, Yan-Jun and Jiang, Hui-Ying and Wang, Zhong-Hua},
  title = {Exploring the Efficacy of Noncovalent SARS‐CoV‐2 Main Protease Inhibitors: A Computational Simulation Analysis Study},
  journal = {Chemistry & Biodiversity},
  year = {2024},
  doi = {10.1002/cbdv.202302089}
}
Kostenlos starten →